Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 205.51% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -11.41% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 8.48% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 1.88% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 27.10% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -5.63% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.12% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 11.74% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 108.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.12% |
| Dec 31, 2025 | 15.29% |
| Sep 30, 2025 | 16.90% |
| Jun 30, 2025 | 11.14% |
| Mar 31, 2025 | 10.83% |
| Dec 31, 2024 | 12.12% |
| Sep 30, 2024 | 16.12% |
| Jun 30, 2024 | 17.01% |
| Mar 31, 2024 | 18.46% |
| Dec 31, 2023 | 16.65% |
| Sep 30, 2023 | 16.96% |
| Jun 30, 2023 | 13.73% |
| Mar 31, 2023 | 14.44% |
| Dec 31, 2022 | 11.83% |
| Sep 30, 2022 | 14.75% |
| Jun 30, 2022 | 19.02% |
| Mar 31, 2022 | 20.35% |
| Dec 31, 2021 | 20.05% |
| Sep 30, 2021 | 21.32% |
| Jun 30, 2021 | 38.61% |